Assertio Holdings, Inc. (ASRT)
| Market Cap | 110.25M |
| Revenue (ttm) | 169.43M |
| Net Income (ttm) | -186.01M |
| Shares Out | 94.67M |
| EPS (ttm) | -1.75 |
| PE Ratio | n/a |
| Forward PE | 11.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,765 |
| Open | 1.13 |
| Previous Close | 1.12 |
| Day's Range | 1.08 - 1.15 |
| 52-Week Range | 0.87 - 8.01 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+490.91%) |
| Earnings Date | Nov 8, 2023 |
About ASRT
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in pa... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ASRT stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 490.91% from the latest price.
News
Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors
LAKE FOREST, Ill., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops...
Assertio Reports Third Quarter 2023 Financial Results
Closed Spectrum Acquisition on July 31, 2023, which diversifies and extends portfolio duration Cash balance at September 30, 2023 of $76.9 million Announces Management Updates
Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023
LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patien...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patien...
Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition
Second Quarter Net Product Sales Increase 13% Year-Over-Year, Generates $18.6 Million in Cash Flow from Operations
Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction
Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products
Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals
Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON...
Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patien...
SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmac...
Assertio Holdings Joins Russell 3000® Index
LAKE FOREST, Ill., June 26, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company, today announced that it has joined the br...
ASRT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Assertio Holdings, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Assertio Holdings, Inc. (NASDAQ: ASRT) and Spectrum Pharmaceuticals, Inc. is fair to As...
Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook
Net Product Sales Increase 18% Year-Over -Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All Stoc...
Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time
LAKE FOREST, Ill., May 05, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patient...
SHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.
NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. ("Spect...
SHAREHOLDER ALERT: Weiss Law Investigates Assertio Holdings, Inc.
NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. ("Assertio" or...
Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patie...
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams
Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older
Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year
Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patie...
Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announc...
Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results
Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year
Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference
LAKE FOREST, Ill., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patien...
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN ® delivers clo...
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
Extends Intellectual Property Protections to 2039 Extends Intellectual Property Protections to 2039